ArticleMolecular medicine reports2018
Nrf2 is a key factor in the reversal effect of curcumin on multidrug resistance in the HCT‑8/5‑Fu human colorectal cancer cell line.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Natural-Origin Compounds as Future Precision Partners in Combination Cancer Therapy.Medicina (Kaunas, Lithuania) · 2026Review
- ZIF-8 Nanocarrier-Based Co-Delivery of Curcumin and 5-Fluorouracil for Synergistic Antitumor Activity in Hepatocellular Carcinoma.International journal of general medicine · 2026Article
- Targeting cytokine and chemokine signaling pathways for enhancing chemo-sensitivity in colorectal cancer.Cell communication and signaling : CCS · 2025Review
- Natural Alternatives in the Treatment of Colorectal Cancer: A Mechanisms Perspective.Biomolecules · 2025Review
- A comprehensive update on the potential of curcumin to enhance chemosensitivity in colorectal cancer.Pharmacological reports : PR · 2025Review
- Nature's weapons: Bioactive compounds as anti-cancer agents.AIMS public health · 2024Review
- The Dual Role of NRF2 in Colorectal Cancer: Targeting NRF2 as a Potential Therapeutic Approach.Journal of inflammation research · 2024Review
- Nanocomposite Hydrogels and Extracellular Matrix-Advantages and Associated Risks.Gels (Basel, Switzerland) · 2023Review
- Curcumin and colorectal cancer: An update and current perspective on this natural medicine.Seminars in cancer biology · 2022Review
- Diet-derived small molecules (nutraceuticals) inhibit cellular proliferation by interfering with key oncogenic pathways: an overview of experimental evidence in cancer chemoprevention.Biologia futura · 2022Review
- Nrf2-Related Therapeutic Effects of Curcumin in Different Disorders.Biomolecules · 2022Review
- The role of polyphenols in overcoming cancer drug resistance: a comprehensive review.Cellular & molecular biology letters · 2022Review
- Curcumin against gastrointestinal cancer: A review of the pharmacological mechanisms underlying its antitumor activity.Frontiers in pharmacology · 2022Review
- Polyphenols of the Mediterranean Diet and Their Metabolites in the Prevention of Colorectal Cancer.Molecules (Basel, Switzerland) · 2021Review
- Research Status and Molecular Mechanism of the Traditional Chinese Medicine and Antitumor Therapy Combined Strategy Based on Tumor Microenvironment.Frontiers in immunology · 2020Review
- Can Nrf2 Modulate the Development of Intestinal Fibrosis and Cancer in Inflammatory Bowel Disease?International journal of molecular sciences · 2019Review
- The Effect of CompoundEvidence-based complementary and alternative medicine : eCAM · 2019Article
- RV-59 suppresses cytoplasmic Nrf2-mediated 5-fluorouracil resistance and tumor growth in colorectal cancer.American journal of cancer research · 2019Article
- Curcumin protects islet cells from glucolipotoxicity by inhibiting oxidative stress and NADPH oxidase activity bothIslets · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug resistance (MDR) is a major concern when using chemotherapy for the treatment of patients with colorectal cancer. MDR modulators are agents that can reverse MDR and, thus, enhance the chemosensitivity of tumor cells. The development of MDR modulators can improve the therapeutic efficacies of MDR in cancer. However, few effective MDR modulators have been identified so far. Curcumin has been reported to be an effective compound in the reversal of MDR in colorectal cancer cells. However, the mechanisms associated with the reversal effect of curcumin on MDR and its regulation of target factors in MDR cells remain to be fully elucidated. 3‑(4,5‑dimethyl‑2‑thiazol)‑2,5‑diphenyltetrazolium bromide assays, flow cytometer apoptosis assays as well as mRNA and protein expression assays were performed in the present study, and the results confirmed the reversal effect of curcumin on HCT‑8/5‑Fu cells and provided evidence that activated nuclear factor erythroid 2‑related factor (Nrf2) deficiency induced by the curcumin altered the B‑cell lymphoma 2 (Bcl‑2) associated X protein/Bcl‑2 expression ratio, which led to the induction of apoptosis in HCT‑8/5‑Fu cells. These results indicated that Nrf2 may have a functional in the reversal effect of curcumin and contribute, at least in part, to the outcomes of chemotherapy in patients with MDR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.